Alcobra Ends Development Of MDX For Adult ADHD, Ponders Strategic Direction

Failing to meet the primary endpoint in its second Phase III study in adult ADHD, the Israeli firm confirms there is no path forward in that indication. Developing MDX for Fragile X syndrome and business development options are under consideration.

Arrows miss target

Alcobra's metadoxine extended-release (MDX) already was walking a tightrope as a potential new therapeutic approach for adult ADHD, but a Phase III clinical trial miss reported Jan. 17 is leading the Israeli biotech to shutter that program and consider its strategic alternatives.

Alcobra revealed only a week earlier that it would conduct a six-month Phase I safety study of MDX to seek...

More from Neurological

More from Therapy Areas